# COXEN (NCT02177695)

> S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02177695
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: SWOG Cancer Research Network
- Conditions: Bladder Cancer
- Interventions: Gemcitabine; Cisplatin; Methotrexate; Vinblastine; Doxorubicin; Filgrastim
- Enrollment: 237
- Primary outcome: Assessment of Whether the Treatment-specific COXEN Score is Prognostic of pT0 Rate
- Primary outcome: Assessment of Whether the Treatment-specific COXEN Score is Prognostic of ≤ pT1 Rate
- Primary outcome: Assessment of COXEN Score as a Predictive Factor Distinguishing Between GC and ddMVAC
- Primary outcome: Correlation Between GC-and ddMVAC-COXEN Score

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 7
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=coxen-nct02177695

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02177695", "email": "<work email>"}; the inbox owner confirms by the emailed link.